BUSINESS WIRE
Major research institution approves investigator-initiated study
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB)
(the "Company"), announced today that the Institutional Review Committee
of a major research institute in New York has approved an
investigator-initiated in vivo study which will evaluate certain topical
nanoviricide™ eye drug candidates. This approved project is designed to
study the effect of different nanoviricide™ drug candidates on herpes
simplex virus (HSV) infection of the cornea. The Company will be
providing the drug candidates free of charge. The principal investigator
is an Associate Professor of Ophthalmology at the Albert Einstein School
of Medicine. She has previously conducted an in vivo study that resulted
in the demonstration of a strong clinical effect of certain nanoviricide
drug candidates against adenovirus induced keratoconjunctivitis in
rabbit eyes.
There are about 50,000 cases of HSV infection of the cornea in the US
alone each year. It is generally caused by HSV Type I. Many of these
cases lead to substantial scarring of the cornea and significantly
reduced vision, which may necessitate corneal transplantation. Current
treatment requires intensive monitoring and specialized procedures
conducted by an ophthalmologist, often lasting several weeks to months.
If the simple eye drops of an anti-herpes nanoviricide candidate produce
rapid clinical resolution of the viral infection, as was found
previously with adenoviral infection of the eye, such nanoviricide
treatment could lead to a significant reduction in the direct health
care costs pertaining to treating this disease. In addition, such an
effective treatment could lead to a significant reduction in the number
of corneal transplants required to treat this number one cause of
corneal blindness in the developed world.
About
NanoViricides:
NanoViricides,
Inc. (www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for viral therapy. The Company's novel nanoviricide™ class
of drug candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs against
a number of viral diseases including H5N1 bird flu, seasonal Influenza,
HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events
could differ materially and substantially from those projected herein
and depend on a number of factors. Certain statements in this release,
and other written or oral statements made by NanoViricides, Inc. are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. You should not place undue reliance on forward-looking statements
since they involve known and unknown risks, uncertainties and other
factors which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation
to publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new
information becomes available in the future. Important factors that
could cause actual results to differ materially from the company's
expectations include, but are not limited to, those factors that are
disclosed under the heading "Risk Factors" and elsewhere in documents
filed by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although it is
not possible to predict or identify all such factors, they may include
the following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful development
of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market
acceptance of our products.